Gene expression analysis in canine epitheliotropic lymphoma - validation cohort
Ontology highlight
ABSTRACT: We performed targeted transcriptomic analysis on archival biopsies from client-owned dogs to examine immune and skin gene expression profiles in spontaneous canine epitheliotropic lymphoma (EL).
Project description:We performed targeted transcriptomic analysis on archival biopsies from client-owned dogs to examine immune and skin gene expression profiles in spontaneous canine epitheliotropic lymphoma (EL).
Project description:We performed a veterinary clinical oncology trial in client-owned dogs to determine if immune modulating drugs could be combined in rational approaches to treat spontaneous canine diffuse large B cell lymphoma (DLBCL).
Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in canine interface dermatitis.
Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine pemphigus mirror those observed in human pemphigus
Project description:We performed a comparative immunology case series study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine erythema multiforme (EM) mirror those observed in human patients.
Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine VKH and vitiligo mirror those observed in human autoimmune pigmentary diseases.
Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine cutaneous lupus erythematosus mirror those observed in human cutaneous lupus.
Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine chronic cutaneous lupus erythematosus (CCLE) with concomitant systemic autoimmunity mirror those observed in human CCLE.
Project description:The hyperglycemic state in diabetes mellitus (DM) induces oxidative stress and inflammation, thus contributing to diabetic tissue damage and associated complications. Astaxanthin, a potent antioxidant carotenoid, has been investigated for its potential in preventing and managing diabetes across various species, but its effect on client-owned dogs is not well-studied. This study explored the impact of astaxanthin supplementation on canine DM using a proteomic approach. A total of 18 client-owned dogs were enrolled: 6 dogs with DM and 12 clinically healthy dogs. The diabetic dogs received their standard treatment regimen alongside daily oral supplementation of 12 mg of astaxanthin (1.5–2.4 mg/kg) for 90 days. Plasma samples were collected at the beginning and end of the study period for proteomic analysis. After astaxanthin supplementation, there were significant alterations in protein expression associated with the complement system, coagulation cascade, JAK-STAT signaling, and protein kinase C signaling, which all contribute to inflammation and oxidative stress. Astaxanthin demonstrated a protective effect against diabetes-associated complications, including insulin resistance, vascular dysfunction, nephropathy, and cardiac complications. These findings highlight the potential of astaxanthin as a complementary therapeutic agent for controlling DM in canines.
Project description:Reflux and aspiration in people cause and exacerbate respiratory diseases in the absence of gastrointestinal (GI) signs. Protein biomarkers in humans detect extra-esophageal reflux (EER) from oropharyngeal (OP) and bronchoalveloar lavage samples. Reflux likely contributes to respiratory disease in dogs. The objectives of this study were to analyze the canine gastric fluid (GF) proteome and compare this to the OP proteome in normal, vomiting/regurgitating and coughing dogs to identify biomarkers for EER/aspiration. Twenty-three client-owned dogs were enrolled. Canine GF samples (n=5) and OP swabs in normal (n=6), vomiting/regurgitating (n=7), and coughing (n=5) dogs were within 2 weeks of sample collection. Protein digests were analyzed by liquid chromatography mass spectrometry (LCMS). Differential abundance (DA) of proteins between groups was evaluated by Fisher Exact test with p< 0.0004 significance level after correction for multiple comparisons. DA was found between all groups (P <0.0001): GF versus normal (n=130 proteins), cough versus normal (n=22 proteins), vomiting/regurgitating versus normal (n=20 proteins). Protein abundance was highly variable between dogs. Gastrointestinal-specific proteins were found in OP swabs from vomiting/regurgitating and coughing dogs but not healthy dogs. In conclusion, the proteomic composition of the OP varies between health and disease. Presence of gastrointestinal-specific proteins in OP of coughing dogs may suggest reflux and/or aspiration as contributing factors. Variable protein abundance warrants investigation into biomarker panels.